Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Market Cap
$6.03B
P/E Ratio
-9.48
1Y Stock Return
60.96%
1Y Revenue Growth
-58.81%
Dividend Yield
0.00%
Price to Book
-433.0
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.
Finnhub
Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy: the SEQUOIA-HCM Trial P. Christian Schulze, MD, PhD1; Theodore P. Abraham, MD2; Roberto...
Finnhub
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Age: the GALACTIC-HF Trial Henri Lu,...
Finnhub
Effect of the Cardiac Myosin Activator Omecamtiv Mecarbil on Ventricular Arrhythmias, Cardiac Arrest, and Sudden Death in HFrEF: the GALACTIC-HF Trial ...
Finnhub
#AHA24 MODIFIABILITY OF POST-EXERCISE OXYGEN UPTAKE RECOVERY PATTERNS: A SUBSTUDY OF THE SEQUOIA-HCM RANDOMIZED TRIAL ...
Yahoo
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CHRS | 35.01% | $94.65M | -58.72% | 0.00% |
EWTX | 34.88% | $2.98B | +397.00% | 0.00% |
RLMD | 33.26% | $89.92M | +1.36% | 0.00% |
KFRC | 30.21% | $1.10B | -8.71% | 0.66% |
BWB | 30.09% | $406.17M | +41.99% | 0.00% |
TEM | 29.54% | $8.50B | 0.00% | 0.00% |
REFI | 29.43% | $311.99M | +6.37% | 11.85% |
NVCR | 27.44% | $1.78B | +34.75% | 0.00% |
AMRX | 26.60% | $2.62B | +88.81% | 0.00% |
GREE | 26.60% | $29.23M | -42.42% | 0.00% |
AXSM | 26.22% | $4.63B | +61.30% | 0.00% |
PFLT | 25.55% | - | - | 11.07% |
APLS | 25.28% | $3.61B | -41.27% | 0.00% |
FOLD | 25.15% | $2.84B | -11.52% | 0.00% |
ATUS | 25.01% | $1.10B | -0.42% | 0.00% |
MARA | 24.93% | $6.39B | +92.63% | 0.00% |
MGTX | 24.84% | $467.36M | +9.12% | 0.00% |
BATRA | 24.51% | $2.62B | +6.13% | 0.00% |
FUN | 24.46% | $4.60B | -16.51% | 0.00% |
UMC | 24.38% | $17.49B | -11.20% | 6.65% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OXBR | -11.32% | $19.05M | +178.18% | 0.00% |
UUU | -11.19% | $4.97M | -41.89% | 0.00% |
XOS | -10.01% | $30.51M | -57.24% | 0.00% |
BACK | -8.59% | $1.76M | -32.90% | 0.00% |
GHG | -8.22% | $180.98M | -36.68% | 0.00% |
SYPR | -6.74% | $32.23M | -26.32% | 0.00% |
PAYX | -5.60% | $50.62B | +18.84% | 2.73% |
NTIC | -5.55% | $132.27M | +24.98% | 2.02% |
SAVA | -4.57% | $1.35B | +25.50% | 0.00% |
LITB | -4.35% | $35.48M | -75.45% | 0.00% |
CMG | -4.29% | $80.02B | +33.62% | 0.00% |
KNOP | -3.85% | $210.40M | +11.75% | 1.68% |
SLE | -3.77% | $8.82M | -63.18% | 0.00% |
COR | -3.53% | $47.48B | +21.20% | 0.86% |
TCTM | -3.53% | $8.10M | -42.99% | 0.00% |
BZUN | -3.45% | $144.84M | -22.09% | 0.00% |
EDSA | -3.39% | $7.11M | -21.79% | 0.00% |
CYCN | -3.10% | $4.77M | -16.19% | 0.00% |
MBI | -3.10% | $335.78M | +105.79% | 0.00% |
MNR | -3.03% | $1.66B | -10.71% | 15.90% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NVDA | 0.05% | $3.61T | +194.35% | 0.07% |
RUM | 0.09% | $1.61B | +13.37% | 0.00% |
OKLO | -0.09% | $2.66B | +111.04% | 0.00% |
SBUX | 0.23% | $111.45B | -5.15% | 2.37% |
FTNT | 0.25% | $69.59B | +72.67% | 0.00% |
DLNG | -0.27% | $161.93M | +73.23% | 0.00% |
CME | 0.30% | $82.76B | +9.21% | 1.98% |
GRAL | -0.33% | $459.22M | -13.00% | 0.00% |
CQP | 0.45% | $25.90B | -6.77% | 5.96% |
FENG | -0.46% | $13.37M | +96.77% | 0.00% |
DAKT | -0.52% | $707.90M | +29.26% | 0.00% |
CASI | 0.57% | $71.56M | -6.32% | 0.00% |
ZTO | 0.58% | $12.58B | -4.71% | 4.73% |
AMBC | 0.61% | $584.50M | -17.09% | 0.00% |
NAPA | -0.62% | $1.63B | +9.61% | 0.00% |
PLMR | -0.66% | $2.84B | +79.77% | 0.00% |
STVN | -0.67% | $4.95B | -32.48% | 0.32% |
DAO | -0.67% | $159.28M | +25.62% | 0.00% |
COCO | -0.69% | $2.01B | +24.49% | 0.00% |
BB | -0.69% | $1.39B | -34.90% | 0.00% |
Current Value
$50.771 Year Return
Current Value
$50.771 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -18.20% | $195.31M | 0.85% |
USDU | -14.89% | $201.97M | 0.5% |
BTAL | -14.67% | $388.04M | 1.43% |
UUP | -13.31% | $309.25M | 0.77% |
CORN | -11.43% | $61.12M | 0.2% |
WEAT | -9.68% | $120.27M | 0.28% |
EQLS | -6.77% | $76.08M | 1% |
FLTR | -6.42% | $1.79B | 0.14% |
CTA | -6.26% | $350.27M | 0.78% |
TAIL | -6.01% | $67.98M | 0.59% |
SHV | -5.80% | $18.13B | 0.15% |
SOYB | -5.54% | $27.32M | 0.22% |
SGOV | -5.54% | $27.53B | 0.09% |
FLRN | -4.53% | $2.33B | 0.15% |
MINT | -3.70% | $11.62B | 0.35% |
GBIL | -3.51% | $5.60B | 0.12% |
DBE | -3.42% | $50.13M | 0.77% |
DBO | -3.32% | $217.57M | 0.77% |
XBIL | -2.68% | $637.70M | 0.15% |
KCCA | -2.64% | $220.51M | 0.87% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 59.83% | $273.87M | 0% |
QQA | 40.10% | $135.01M | 0% |
IBB | 33.25% | $6.66B | 0.45% |
EFAA | 32.82% | $117.38M | 0% |
XBI | 32.73% | $6.58B | 0.35% |
XPH | 30.36% | $157.87M | 0.35% |
PINK | 30.00% | $161.15M | 0.5% |
BBH | 28.85% | $397.87M | 0.35% |
PBE | 28.34% | $258.53M | 0.58% |
FBT | 27.63% | $1.11B | 0.56% |
IBHG | 27.36% | $175.24M | 0.35% |
IHE | 27.23% | $596.23M | 0.39% |
PTH | 26.96% | $143.31M | 0.6% |
BKCH | 26.66% | $204.99M | 0.5% |
FHLC | 26.62% | $2.73B | 0.084% |
IWC | 26.23% | $933.99M | 0.6% |
VHT | 26.10% | $17.06B | 0.1% |
BITQ | 25.73% | $189.55M | 0.85% |
SATO | 25.54% | $10.34M | 0.6% |
DAPP | 25.42% | $184.93M | 0.51% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLOT | 0.38% | $7.31B | 0.15% |
PDBC | -0.45% | $4.40B | 0.59% |
BILZ | 0.50% | $563.02M | 0.14% |
FMF | -0.63% | $244.61M | 0.95% |
IBDP | -0.69% | $2.11B | 0.1% |
COMT | -0.77% | $829.06M | 0.48% |
ULST | 0.94% | $535.47M | 0.2% |
BOXX | -0.96% | $4.43B | 0.1949% |
XHLF | -0.96% | $874.27M | 0.03% |
HIGH | 1.15% | $302.78M | 0.51% |
XONE | 1.22% | $548.88M | 0.03% |
TPMN | 1.36% | $40.60M | 0.65% |
IBTE | 1.45% | $1.70B | 0.07% |
DBC | -1.46% | $1.39B | 0.87% |
HDRO | -1.62% | $164.26M | 0.3% |
JBBB | -1.71% | $1.26B | 0.49% |
DFSD | 1.74% | $3.63B | 0.16% |
DBA | -1.75% | $755.88M | 0.93% |
TBIL | -1.81% | $4.38B | 0.15% |
GSG | -1.88% | $914.42M | 0.75% |